This story has been updated to include comments from Rosetta's president and CEO.

Rosetta Genomics
this week announced that it has granted the right to market and sell its three microRNA-based diagnostics in the US to drug and diagnostic firm Prometheus Laboratories.

The deal is the latest move by Rosetta to find commercialization partners for its existing products as it shifts its focus onto non-invasive tests designed to screen for, rather than diagnose, disease.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: mouse genome functional analysis, more sensitive chromatin immunoprecipitation, and more.

The Center for Data Innovation and HealthITNow argue for re-building of genomic research infrastructure.

A Senate committee has unanimously approved a bill to require articles resulting from federally funded projects to be made publicly available, according to ScienceInsider.

The US is heading toward another budget showdown, Nature News says.